Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04597528
Other study ID # 42/19/IEC/JMMC&RI
Secondary ID U1111-1245-7675
Status Completed
Phase
First received
Last updated
Start date October 17, 2019
Est. completion date May 17, 2021

Study information

Verified date March 2022
Source Jubilee Mission Medical College and Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Adverse events are considered to increase in pregnancies extending beyond 39 weeks. For multiparous patients, especially those with a favourable cervix, it is perhaps easy to justify an elective induction at 39 weeks given the low risk of caesarean section. However, for nulliparous patients the current evidence, derived mainly from retrospective observational studies, does not allow a clear recommendation with the exception perhaps of the recent A Randomized Trial of Induction Versus Expectant Management (ARRIVE) trial. Given the reported increased risks of adverse events in pregnancies extending beyond 39 weeks it has been hypothesized that a policy of planned elective induction at 39 weeks could improve outcomes for the infant and the mother. There is a trend towards an increased rate of elective labour induction in pregnancies at 39 weeks, indicating that practitioners are more commonly using elective induction at this gestational age. The practice in India varies slightly from institute to institute. The investigator intend to study the maternal and perinatal outcome, after elective induction of labour, at thirty nine weeks and zero days upto thirty nine and six days, amongst nulliparous singleton pregnancies followed up for the duration of their hospital stay, in Jubilee Mission Medical College and Research Institute (JMMC and RI).


Recruitment information / eligibility

Status Completed
Enrollment 315
Est. completion date May 17, 2021
Est. primary completion date April 16, 2021
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: 1. Nulliparous - no previous pregnancy beyond 20 weeks 2. Singleton gestation. 3. Undergoing elective induction between 39weeks and 0days -39weeks and 6 days based on clinical information and evaluation of the earliest ultrasound as described in Gestational Age 4. Consenting to be part of the study Exclusion Criteria: 1. Plan for caesarean delivery or any contraindication to vaginal delivery 2. Foetal demise or known major foetal anomaly

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Elective Induction
All patients admitted to the labour room would be approached to be enrolled in the study. Those satisfying the inclusion and exclusion criteria would be prospectively enrolled to the study after procuring an informed consent. If a patient appears to meet the criteria for the study, she will be told about the study and asked for written informed consent to participate. Consent may be obtained anytime from 34 weeks 0 days to 38 weeks 6 days of gestation. Data would be procured on a pre set proforma, entered in real time and safely stored. The data would later be abstracted to an excel sheet.

Locations

Country Name City State
India Jubilee Mission Medical College and Research Institute Thrissur Kerala

Sponsors (1)

Lead Sponsor Collaborator
Jubilee Mission Medical College and Research Institute

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Caesarean Section (CS) Number of participants who underwent CS measured in percentage Till discharge from hospital or upto 4 days from day of delivery whichever is later
Primary Number of neonates requiring intensive care Incidence of admission to neonatal intensive care unit (NICU) requiring cardio respiratory support within the first 24 hours of birth.
Cardio respiratory support defined as needing any of the following within the first 24 hours of birth
Cardiopulmonary resuscitation (CPR)
invasive mechanical ventilatory care with a definitive airway
high flow nasal cannula (HFNC)
nasal continuous positive airway pressure (CPAP)ventilation
24 hours from birth
Secondary Time to delivery (induction to delivery time ) Time taken from induction of delivery to delivery of the baby measured in hours and minutes 24 hours
Secondary Number of study participants with chorioamnionitis Chorioamnionitis, documented as a clinical diagnosis before delivery Diagnosed at anytime, through delivery, upto 24 hours after birth
Secondary Number of participants with Postpartum hemorrhage Postpartum hemorrhage, defined as answering "yes" for any of the questions as per a predefined checklist for Upto 12 weeks from day of delivery
Secondary Neonatal Mortality Number of neonatal deaths Antepartum upto 30 days post delivery
Secondary APGAR</= 7 at birth The Apgar score is based on a total score of 1 to 10. The higher the score, the better the baby is doing after birth. A score of 7, 8, or 9 is normal and is a sign that the newborn is in good health. Upto 5 mins after birth
Secondary Number of infants with meconium aspiration syndrome (MAS) Number of infants with MAS Delivery through discharge or upto 4 days post delivery whichever is earlier
See also
  Status Clinical Trial Phase
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT06258902 - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed NCT05487196 - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia Phase 2
Completed NCT03750968 - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects Phase 2
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT06069869 - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06069856 - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06079918 - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania Phase 3
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A